ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. vTv Therapeutics's annualizedNet Income for the quarter that ended in Mar. 2026 was €83.50 Mil.
vTv Therapeutics's average Total Assets over the quarter that ended in Mar. 2026 was €81.12 Mil. Therefore, vTv Therapeutics's annualized ROA % for the quarter that ended in Mar. 2026 was 102.93%.
The historical rank and industry rank for vTv Therapeutics's ROA % or its related term are showing as below:
FRA:5VT0'
s ROA % Range Over the Past 10 Years
Min: -146.36 Med: -64.9 Max: 3.25
Current: 3.25
During the past 13 years, vTv Therapeutics's highest ROA % was 3.25%. The lowest was -146.36%. And the median was -64.90%.
FRA:5VT0's ROA % is ranked better than 85.16% of 1422
companies
in the Biotechnology industry
Industry Median: -32.87
vs FRA:5VT0: 3.25
vTv Therapeutics (FRA:5VT0) ROA % Explanation
ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A banks ROA % is typically well under 2%.
Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:
Note:
The Net Income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.
E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.
vTv Therapeutics ROA % Related Terms
vTv Therapeutics ROA % Historical Data
* Premium members only.
The historical data trend for vTv Therapeutics's ROA % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, vTv Therapeutics's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
vTv Therapeutics ROA % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, vTv Therapeutics's ROA % distribution charts can be found below:
* The bar in red indicates where vTv Therapeutics's ROA % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
ROA % is displayed in the 30-year financial page.
vTv Therapeutics (FRA:5VT0) has a ROA % of 102.93% as of Mar. 2026. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on vTv Therapeutics and its competitors. According to the industry distribution chart, vTv Therapeutics ranks #211 out of 1422 companies in the Biotechnology industry, placing it in the top 14.8%.
Is vTv Therapeutics' ROA % too high?
vTv Therapeutics' current ROA % is 102.93%. Based on the distribution chart, vTv Therapeutics ranks #211 out of 1422 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, vTv Therapeutics has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does vTv Therapeutics' ROA % compare to CRDF and GUTS?
According to the Biotechnology industry distribution chart, vTv Therapeutics ranks #211 out of 1422 companies for ROA %. This places vTv Therapeutics in the top 15% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROA % for a Biotechnology company?
A good ROA % depends on the Biotechnology industry context. However, ROA % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROA % mean?
A high ROA % can signal that a stock is expensive relative to its fundamentals. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on vTv Therapeutics and its competitors. vTv Therapeutics's current ROA % is 102.93%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is vTv Therapeutics stock overvalued right now?
vTv Therapeutics (FRA:5VT0) has a current ROA % of 102.93%. The stock's GF Value™ is €6,491.15, compared to a current price of €30.80 — trading 99.5% below its estimated fair value. The current ROA % is 102.93%. vTv Therapeutics' overall GF Score™ is 35/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROA % calculated?
ROA % is calculated from a company's financial statements. For vTv Therapeutics (FRA:5VT0), the current ROA % is 102.93% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is vTv Therapeutics (FRA:5VT0) Overvalued in 2026?
Based on GuruFocus' analysis, vTv Therapeutics stock appears to be undervalued.
The current stock price of €30.80 is trading 99.5% below its estimated GF Value™ of €6,491.15.
Key valuation signals for FRA:5VT0:
ROA %: 102.93%
GF Value™: €6,491.15 vs. price of €30.80 (99.5% below fair value)
No single metric tells the full story. See the FRA:5VT0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
vTv Therapeutics Inc is a late-stage biopharmaceutical company focused on developing oral, small-molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. Its clinical pipeline is led by cadisegliatin (TTP399), a novel, small-molecule, liver-selective glucokinase activator (GKA) currently being evaluated as a potential oral adjunctive therapy to insulin for the treatment of type 1 diabetes (T1D). In addition, the company is also engaged in the research and development of other candidates in its pipeline through collaborations with academic partners and license agreements, which include TTP273, HPP737, TTP-RA, Mavodelpar (HPP593), HPP971, and HPP3033, being studied and developed to counter various chronic diseases.
35GF Score
Get the complete analysis for FRA:5VT0
ROA % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:5VT0 has been successfully added to your 
